In August 2018, Huicheng technology invested 15 million yuan in Zhenji intelligent, holding 15% equity of Zhenji intelligent, becoming the only manufacturer of unmanned distribution robots and other intelligent Eligibility to buy stocksrobots developed and designed by Zhenji intelligent, and further improved the high-end intelligent manufacturing layout.
Diagnostics, find) is a global non-profit organization dedicated to promoting the development and innovation of diagnostic technology. In 2020, who has formally launched strategic cooperation with the global innovation diagnosis foundation. This cooperation is mainly aimed at strengthening the integration of resources, especially in some poor countries with weak health conditions. Cooperation can also narrow the country's diagnostic technology gap and improve disease prevention and surveillance capabilities. "
Innovation is the driving force of Industrial Bank Guangzhou Branch's continuous development, and prudence and rule-based are the cornerstone and bottom line of business development. Guangzhou Branch of Industrial Bank of China sticks to the lifeline of asset quality. By the end of June 2020, the balance of non-performing loans and the ratio of non-performing loans of the branch continued to decline, and the asset quality ranked in the forefront of local joint-stock banks of the same type, with obvious comparative advantages.
Another consumer complained that on July 6, another consumer posted a complaint saying that they would enroll in Zhongye online school to study fire engineer course in January 2019. During this period, the head teacher first asked the teacher to sign up for the four week secret script live class, and then asked the newspaper to cover the class. He revealed that he could obtain the examination questions through internal channels a few days before the examination. "The head teacher doesn't care how you study at all. He just lets students spend money to buy classes, which makes me not even able to take credit cards." Source: according to the public data of complaints gathering, the vocational training and employment guidance provided by Zhongye online school include engineering, real estate, postgraduate entrance examination, teacher qualification certificate, finance and economics, medicine and education. In 2014, Zhongye e-school opened a five-dimensional training system, with an annual enrollment of more than 230000, and then launched an offline market layout based on Beijing and radiating across the country. The full name of Zhongye online school is Beijing Zhongye Huizhi Education Technology Co., Ltd., which was registered in November 2010. Hong Wei, a natural person, is the largest shareholder with 55.5% shares; Yu Guanguan is the second largest shareholder, manager and executive director of 33% shares. Beijing Zhongye Huizhi Education Technology Co., Ltd. Haidian Branch is its branch company, which was registered and established in March 2018. Hong Wei indirectly holds 55.5% equity of the company and is its controller. Part of the equity penetration map of Beijing Zhongye Huizhi education and Technology Co., Ltd. (source: tianyancha) tianyancha also shows that in October 2016, Beijing Zhongye Huizhi Education Technology Co., Ltd. was fined 10000 yuan for using an unregistered trademark as a registered trademark; since 2018, the enterprise has been sued repeatedly for disputes over education and training contracts, infringement of the right to network dissemination of information of works. Source: tianyancha
Zhao Tao, chairman of Buchang Pharmaceutical Co., Ltd., said that the company will give full play to the advantages of the original global strategy of natural medicine and traditional Chinese medicine prescription patent medicine, practice the brand-new biopharmaceutical strategy, base on the tripartite layout of traditional Chinese medicine, deeply dig biopharmaceutical and enter the vaccine field, and make every effort to build the whole industrial chain of biopharmaceutical based on the platform of pharmaceutical e-commerce and OTC, so as to become a leading enterprise in China's pharmaceutical industry and a global excellent enterprise To achieve "China's Johnson & Johnson, the step size of the world". "
In Gu'an, Hebei Province, Huaxia Xingfu has introduced more than 30 upstream and downstream enterprises in the display industry, including BOE, vicino, DingCai technology, etc., andEligibility to buy stocks a 100 billion level new display industrial cluster has emerged, and Gu'an has been approved as the first national demonstration area for the creation of famous photoelectric display brands""."
"Every reporter Yao Yanan, every editor Xiao Ruidong
Next, Suning's work is still centered on the comprehensive upgrading of services. With the deepening of openness, Suning will evolve from "fighting alone" to "fighting side by side" with many partners, accelerate the transformation from retailer to retail service provider, improve the comprehensive service for users, businesses, partners and employees, and focus on user value, ecological value and long-term price Value, enabling retail ecology, and achieving "valuable development and beneficial growth" together with users and partners. "
On July 15, Hongyun Huaning launched the first international multi center clinical trial of gma301, the world's first anti pulmonary hypertension drug. The trial will be conducted in clinical research centers of about 10 famous hospitals in China and the United States. At present, the cardiovascular clinical research center of Peking Union Medical College Hospital will take the lead in carrying out the world's first subject enrollment. It is understood that gma301 is an antibody drug targeting endothelin receptor, which is independently developed by Hongyun Huaning and has completely independent intellectual property rights. It is intended to be used in the treatment of pulmonary hypertension. Pulmonary hypertension is a life-threatening and rare progressive disease, which is caused by small peripheral pulmonary artery occlusion caused by proliferation of endothelial cells and smooth muscle cells and in situ thrombosis. Progressive occlusion of the distal artery can lead to increased pulmonary vascular resistance, elevated pulmonary arterial pressure, right heart failure, severe weakness, and eventually death. Pulmonary hypertension usually has no definite cause (e.g. idiopathic pulmonary hypertension). Genetic factors, drugs or toxins may induce pulmonary hypertension. Pulmonary hypertension is also associated with collagen vascular disease, congenital heart disease, human immunodeficiency virus, portal hypertension or schistosomiasis. According to the introduction, preclinical and early clinical studies have shown that gma301 is significantly better than existing targeted drugs in terms of safety, and has a good control effect on the core indicators of pulmonary hypertension, which is expected to transform the incurable pulmonary hypertension into a chronic disease controlled by drugs. Up to now, the drug has been licensed for clinical trials in China, the United States and Australia, as well as the "orphan drug" qualification of the United States,